Select Medical Holdings Corporation has completed its acquisition by a consortium led by Executive Chairman Robert A. Ortenzio, Senior Executive Vice President Martin F. Jackson, and private equity firm Welsh, Carson, Anderson & Stowe. The all-cash deal values the company at approximately $3.9 billion, with shareholders receiving $16.50 per share, a premium of about 18% over the unaffected share price as of November 24, 2025. The acquisition will become effective on July 1, 2026, at which point Select Medical's common stock will cease trading on the New York Stock Exchange. The company's current officers, including Ortenzio and Jackson, will continue to lead the business. Stockholders approved the transaction at a special meeting on June 26, 2026.
Select Medical HoldingsAcquisition at 18% premium over unaffected price, shareholders receive $16.50 per share.
WCAS leads consortium acquiring Select Medical, a $3.9B deal.